<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01533051</url>
  </required_header>
  <id_info>
    <org_study_id>Quit Anti-viral therapy</org_study_id>
    <nct_id>NCT01533051</nct_id>
  </id_info>
  <brief_title>Prospective Observational Cohort Study for the Durability of Anti-viral Therapy in Patients With Chronic Hepatitis B</brief_title>
  <official_title>Phase IV Study of Durability of Anti-viral Therapy in Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the off-treatment sustained virological and
      biochemical response in chronic hepatitis B patients following the guideline by the Asian
      Pacific Association for the Study of the Liver (APASL) in Korea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the recommendation by the Asian PAcific Association for the Study of the Liver(APASL),
      antiviral drug is recommended to stop when HBeAg seroconversion has developed for more than 6
      months among HBeAg-positive patietns. For HBeAg-negative patients, the APASL consensus
      recommended stopping anti-viral treatment when HBV DNA remained undetectable for three
      separates occasion 6 months apart. Nontheless, approximately 25% to 50% of the patients still
      develop hepatitis relapse after stopping anti-viral therapy even if these recommendations are
      followed. In this study, the investigators aimed to investigated the off-treatment sustained
      response in chronic hepatitis B parients following the stopping anti-viral treatment
      guideline in Korea.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virological response after stopping anti-viral treatment</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The proportion of patients with sustained virological response after stopping anti-viral treatment</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Chronic hepatitis B</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Initially, 30ml of heparinized peripheral blood will be obtained from each subjects. After
      then, 10ml of heparinized peripheral blood will be additionaly obtained at every 3 months
      follow-up visit.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic Hepatitis B patients under anti-viral therapy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  More than 20 years old

          -  Chronic hepatitis B patients under anti-viral therapy

               1. In HBeAg-positive patient; if HBeAg seroconversion with undetectable HBV DNA is
                  documented on two separate occasions at least 6 months

               2. In HBeAg-negative patient; if undetectable HBV DNA has been documented on three
                  separate occasions 6 months apart

        Exclusion Criteria:

          -  Patients who had chronic liver disease due to hemochromatosis, autoimmune hepatitis,
             drug-induced hepatitis, or thalassemia

          -  Patients who suffered from other chronic medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Hoon Ahn, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Internal Medicine, Yonsei Universtiy College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hana Park, MD</last_name>
    <phone>02-2228-1931</phone>
    <email>PHN223@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sang Hoon Ahn</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hana Park, MD</last_name>
      <phone>02-2228-1931</phone>
      <email>PHN223@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Kwang-Hyub Han, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Do Young Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Yong Park, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seung Up Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hana Park, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young Eun Chon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2012</study_first_submitted>
  <study_first_submitted_qc>February 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2012</study_first_posted>
  <last_update_submitted>May 7, 2012</last_update_submitted>
  <last_update_submitted_qc>May 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Sang Hoon Ahn</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>Nucleos(t)ide analogue</keyword>
  <keyword>Antiviral treatment</keyword>
  <keyword>Korea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

